Eli Lilly and Company (ETR:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 574.77B |
| Revenue (ttm) | 45.35B |
| Net Income (ttm) | 11.75B |
| Shares Out | n/a |
| EPS (ttm) | 13.02 |
| PE Ratio | 48.91 |
| Forward PE | 26.76 |
| Dividend | 5.29 (0.82%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 2,611 |
| Average Volume | 4,133 |
| Open | 648.10 |
| Previous Close | 649.60 |
| Day's Range | 637.40 - 654.30 |
| 52-Week Range | 535.80 - 888.30 |
| Beta | 0.47 |
| RSI | 55.41 |
| Earnings Date | Oct 30, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Inside the Race to Launch GLP-1 Weight-Loss Pills
Plus, solar cars, Meta's new glasses and AI financial agents, in this edition of The Future of Everything newsletter.
19.9% of VHT Holdings Seeing Recent Insider Buys
A look at the weighted underlying holdings of the Vanguard Health Care ETF (VHT) shows an impressive 19.9% of holdings on a weighted basis have experienced insider buying within the past six months. E...
This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy?
Eli Lilly's initiative could make the company even more successful than it already is.
Eli Lilly (LLY) Positioned for Market Share Gains Amid Competitor's Downsizing
Eli Lilly (LLY) Positioned for Market Share Gains Amid Competitor's Downsizing
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
No more need for needles: A new generation of GLP-1 weight-loss drugs in pill form is coming closer
Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
Eli Lilly (LLY) Advances Tirzepatide for Pediatric Diabetes
Eli Lilly (LLY) Advances Tirzepatide for Pediatric Diabetes
Eli Lilly posts late-stage trial win for Ozempic in children and adolescents with diabetes
Eli Lilly (LLY) stock is in focus as its popular GLP-1 med Mounjaro hits main goals in a Phase 3 trial for children and adolescents with type 2 diabetes. Read more here.
Novo Nordisk shares shoot up amid promising results for anti-obesity pill
Stock climbs above £6.5bn in early trading as trial shows ‘significant weight loss’ for pill version of Wegovy Business live – latest updates The value of the drugmaker Novo Nordisk has shot up by mor...
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.
In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.
Lilly :Mounjaro Shows 2.2% A1C Drop In Phase 3 Trial For Children & Adolescents With Type 2 Diabetes
(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from SURPASS-PEDS, the first Phase 3 trial evaluating the safety and efficacy of Mounjaro (tirzepatide)—a GIP/GLP-1 dual receptor agonist...
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Mounjaro
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Mounjaro
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting...
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week exten...
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms
Eli Lilly (LLY) Faces FDA Scrutiny over Drug Promotion Practices
Eli Lilly (LLY) Faces FDA Scrutiny over Drug Promotion Practices
Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs
Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs
Jim Cramer says Eli Lilly's obesity pill could be more of a 'lifetime drug' than shots
"Persistence is the enemy of these [GLP-1 drugs] right now," CNBC's Jim Cramer said Wednesday.
Eli Lilly (LLY) Reports Superior Diabetes Drug Results
Eli Lilly (LLY) Reports Superior Diabetes Drug Results